VIGR/GPR126 Antibody (1044430) [Alexa Fluor® 488]

• Applications: Flow
• Clone: 1044430
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

VIGR/GPR126 Antibody (1044430) [Alexa Fluor® 488] Summary

• Immunogen: Human embryonic kidney cell HEK293-derived human VIGR/GPR126 protein
  Cys38-Lys437
  Accession # AAH75798.1
• Specificity: Detects human VIGR/GPR126 protein in direct ELISAs.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Reconstitution Instructions: Reconstitution default not known

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

VIGR (Vascular Inducible G Protein-coupled Receptor), also known as ADGRG6, DREG, and GPR126, is a neuronal 7 TM pass (G protein)-coupled receptor (GPCR) involved in myelination and glial and Schwann cell development (1, 2). Human VIGR cDNA encodes a 1221 amino acid (aa) residue membrane protein with a 37 aa signal peptide, a 825 aa extracellular domain (ECD) with 27 potential N-linked glycosylation sites, seven transmembrane segments that span between aa 863 and aa 1113, and a 108 aa residue cytoplasmic domain. Within ECD human VIGR shares 83% aa sequence identity with mouse and rat VIGR. VIGR is essential for the development of diverse organs (1, 2). Type IV collagen, a major constituent of the basement membrane, binds to VIGR and activates its signaling function (3). This interaction stimulated the production of cAMP in rodent Schwann cells, which require VIGR activity to differentiate, and in human embryonic kidney (HEK293) cells expressing exogenous VIGR. Laminin-211 binds a novel laminin-binding domain in VIGR N-terminal fragment between aa 446 and 807 (4). VIGR-Laminin-211 interactions regulate terminal differentiation and myelination by ensuring appropriate levels of cAMP for a given stage of Schwann cell development (4).

1. Rughetti, A. et al. (2005) J. Immunol. 174:7764.
2. Engelstaedter, V. et al. (2012) BMC Cancer 12:600.
3. Taylor-Papadimitriou, J. et al. (1999) Biochim. Biophys. Acta 1455:301.
4. Geng, Y. et al. (2012) Front Oncol. 2:76.
5. Tanida, S. et al. (2013) J Biol Chem. 288:31842.
6. Beatson, R. et al. (2016) Nat Immunol. 17:1273.
7. Piyush, T. et al. (2017) Cell Death Differ. 24:1937.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.